MEDIWOUND LTD (MDWD) Stock News
NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD
MDWD Latest News, Press Relases and Analysis
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
MediWound (MDWD) Q1 2025 Earnings Call Transcript
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 89.23% and 22.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: HQY
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity...
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time...
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 13.33% and 1.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BHST
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -36.49% and 4.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: OPTN
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of -9.68% and 52.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MGX
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -633.33% and 71.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FGEN
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: TBPH
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65%...
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue...
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric...
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound to Report Third Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA...
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue...